Peer-reviewed veterinary case report
Detecting BRAF mutation in dog bladder and prostate cancer
By Aeschlimann, Leonore et al.·Published in Veterinary and comparative oncology·2024·Institute of Animal Pathology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effective detection of BRAFmutation in canine urothelial and prostate carcinomas using immunohistochemistry.
- Species:
- dog
Plain-English summary
A study found that a specific mutation (BRAF mutation) was present in many dogs with bladder cancer (urothelial carcinoma) and prostate cancer. Researchers tested tissue samples from 122 dogs with bladder cancer and 21 with prostate cancer using a new method called immunohistochemistry (IHC), which can identify the mutated protein. They discovered that about 59% of the bladder cancer cases and 65% of the prostate cancer cases showed the mutation. This method was very accurate and could help veterinarians screen for this mutation in dogs, potentially guiding treatment options in the future.
People also search for: dog bladder cancer treatment · dog prostate cancer symptoms · BRAF mutation in dogs · canine cancer testing methods
Abstract
Canine urothelial carcinoma (UC) and prostate carcinoma (PC) frequently exhibit the BRAFmutation, akin to the BRAFmutation common in various human cancers. Since the initial discovery of the BRAF mutation in canine cancers in 2015, PCR has been the standard method for its detection in both liquid and tissue biopsies. Considering the similarity between the canine BRAFand human BRAFmutations, we hypothesized that immunohistochemistry (IHC) using a BRAF-specific antibody could effectively identify the canine mutant BRAFprotein. We tested 122 canine UC (bladder n = 108, urethra n = 14), 21 PC, and benign tissue using IHC and performed digital droplet PCR (ddPCR) on all 122 UC and on 14 IHC positive PC cases. The results from ddPCR and IHC were concordant in 99% (135/136) of the tumours. Using IHC, BRAFwas detected in 72/122 (59%) UC and 14/21 (65%) PC. Staining of all benign bladder and prostate tissues was negative. If present, mutant BRAF staining was homogenous, with rare intratumour heterogeneity in three (4%) cases of UC. Additionally, the BRAFmutation was more prevalent in tumours with urothelial morphology, and less common in glandular PC or UC with divergent differentiation. This study establishes that BRAF-specific IHC is a reliable and accurate method for detecting the mutant BRAFprotein in canine UC and PC. Moreover, the use of IHC, especially with tissue microarrays, provides a cost-efficient test for large-scale screening of canine cancers for the presence of BRAF mutations. This advancement paves the way for further research to define the prognostic and predictive role of this tumour marker in dogs and use IHC to stratify dogs for the treatment with BRAF inhibitors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38659202/